Antibody-mediated cell depletion therapies in multiple sclerosis

Development of disease-modifying therapies including monoclonal antibody (mAb)-based therapeutics for the treatment of multiple sclerosis (MS) has been extremely successful over the past decades.Most of the mAb-based therapies approved for MS deplete immune mcclelland reclining sofa cell subsets and act through activation of cellular Fc-gamma recep

read more